UNSPSC 51312100: Antihistamine or H1 blocker cyclic s-oxides and dibenzazepines and dibenzoxepins and glyoxylates

This classification denotes Antihistamine or H1 blocker drugs made from or based in part on cyclic s-oxides, dibenzazepines, dibenzoxepins, or glyoxylates

UNSPSC 51312100 Antihistamine or H1 blocker cyclic s-oxides and dibenzazepines and dibenzoxepins and glyoxylates is a Class code, but the recent state and local activity tagged to it shows a significant mismatch between the nominal pharmaceutical scope and what is actually being procured. Seminole County, Florida solicited naloxone and safe drug deactivation systems through an IFB, neither of which aligns with the antihistamine and dibenzazepine chemistry the code nominally describes. The procurement itself reflects genuine state and local demand — naloxone is a critical opioid-overdose reversal agent distributed through public health channels, and drug deactivation systems serve harm-reduction and evidence-disposal functions — but the UNSPSC coding here does not reflect that substance. The issuing body is a county government pursuing community health initiatives with quarterly delivery cycles and fixed-fee contracting.

The single recent opportunity in the source is Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026, with a response deadline of July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for delivery to the Seminole County Community Health Building in Sanford. Vendors must include all shipping and delivery costs in pricing, meet E-Verify and drug-free workplace requirements, maintain workers' compensation and liability coverage, and accept a three-month probationary termination clause. The contract carries a two-year initial term with a one-year renewal option and potential FEMA funding. Given the narrow activity window and the coding misalignment, this Class code shows limited recent state and local procurement activity under its pharmaceutical taxonomy scope.